Novel Therapies for Hidradenitis Suppurativa Produce Rapid, Deepening Responses

(MedPage Today) -- DENVER -- Two therapeutic candidates for severe hidradenitis suppurativa (HS) achieved major responses that proved durable in randomized trials reported here. The IL-17A/F inhibitor sonelokimab achieved at least 75% skin clearance...
Source
MedPage Today
Opens original article in a new tab



